UK markets open in 2 hours 1 minute
  • NIKKEI 225

    29,069.99
    +194.76 (+0.67%)
     
  • HANG SENG

    29,210.31
    +327.85 (+1.14%)
     
  • CRUDE OIL

    73.37
    +0.07 (+0.10%)
     
  • GOLD FUTURES

    1,776.00
    -0.70 (-0.04%)
     
  • DOW

    34,196.82
    +322.58 (+0.95%)
     
  • BTC-GBP

    24,940.92
    +1,400.49 (+5.95%)
     
  • CMC Crypto 200

    835.42
    +48.80 (+6.20%)
     
  • ^IXIC

    14,369.71
    +97.98 (+0.69%)
     
  • ^FTAS

    4,051.12
    +11.72 (+0.29%)
     

2021 Fibromyalgia Market Spotlight Report

·2-min read

Dublin, June 11, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Fibromyalgia" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Fibromyalgia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, prevalence data, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

The approved drugs in the fibromyalgia space target dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, serotonin reuptake, and voltage-gated calcium channels. All of the marketed drugs for fibromyalgia are administered via the oral route.

The majority of industry-sponsored drugs in active clinical development for fibromyalgia are in Phase II. Therapies in development for fibromyalgia focus on a wide variety of targets. These drugs are most commonly administered via the oral route.

High-impact upcoming events in the fibromyalgia space comprise topline Phase III trial results for Tonmya, topline Phase II trial results for NYX-2925, and topline Phase IIb trial results for IMC-1.

The overall likelihood of approval of a Phase I pain asset is 5.6%, and the average probability a drug advances from Phase III is 55.9%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.8 years in the overall neurology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for fibromyalgia have been in the late phases of development, with 69% of trials in Phase III-IV, and 31% in Phase I-II.

The US has a substantial lead in the number of fibromyalgia clinical trials globally. Germany, Spain, and the UK lead the major European markets, while India has the top spot in Asia.

Clinical trial activity in the fibromyalgia space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for fibromyalgia, with 23 trials.

Pfizer leads industry sponsors with the highest overall number of clinical trials for fibromyalgia, followed by AbbVie.


Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Disease definition

  • Symptoms

  • Patient subtypes

  • Risk factors

  • Diagnosis

TREATMENT

  • Pharmacological therapies

EPIDEMIOLOGY

  • Fibromyalgia prevalence

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Tonmya for Fibromyalgia (December 7, 2020)

  • IMC-1 for Fibromyalgia (August 28, 2020)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Sawai Claims A First With Japanese Pregabalin Launch

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Exagen Licenses Ohio State's Fibromyalgia Diagnosis IP

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status

  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/8xy1dn

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting